Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29092373 | 0.90 | CYP4F2 (0.33) | CYP4F2CYP4A11RET | |
| SCHEMBL27187892 | 0.90 | CYP4F2 (0.33) | CYP4F2CYP4A11RET | |
| SCHEMBL27187897 | 0.90 | CYP4F2 (0.33) | CYP4F2CYP4A11RET | |
| SCHEMBL24606844 | 0.84 | CYP4F2 (0.35) | CYP4F2CYP4A11RET | |
| SCHEMBL31327358 | 0.80 | CYP4F2 (0.34) | CYP4F2CYP4A11RET | |
| SCHEMBL27188228 | 0.79 | RET (0.33) | RET | |
| SCHEMBL27188227 | 0.79 | RET (0.33) | RET | |
| SCHEMBL29712243 | 0.79 | RET (0.33) | RET | |
| SCHEMBL31411345 | 0.78 | ATR (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL31411354 | 0.78 | ATR (0.36) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2022147246-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | CYP4F2 1846/4885CYP4A11 1832/4885RET 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.